Dottorato in Medicina Molecolare

Chiarle R, Zhang Y, Frock RL, Lewis SM, Molinie B, Ho YJ, Myers DR, Choi VW, Compagno M, Malkin DJ, Neuberg D, Monti S, Giallourakis CC, Gostissa M, Alt FW.Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell  2011 Sep 30;147(1):107-19 (IF 32.401)

Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R,Pasqualucci L. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009 Jun 4;459(7247):717-21 (IF 34.48)

Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla-Favera R, Pasqualucci L, Bhagat G, Bertoni F. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009 May 14;113(20):4918-21 (IF 10.56)

 Pasqualucci L, Bhagat G, Jankovic M, Compagno M,  Smith P, Muramatsu M, Honjo T, Morse HC 3rd, Nussenzweig MC, Dalla-Favera R. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008 Jan; 40(1): 108-12 (IF 34.28)

Rocci A, Ricca I, Della Casa C, Longoni P, Compagno M, Francese R, Lobetti Bodoni C, Manzini P, Caracciolo D, Boccadoro M, Ferrero D, Ladetto M, Carlo Stella C, Tarella C. Long-term lymphoma survivors following high dose chemotherapy and autograft: Evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. Exp Hematol  2007 Apr; 35(4):673-81 (IF 3.106)

Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, De Marco F, Astolfi M, Monitillo L, Vallet S, Calvi R, Ficara F, Omede’ P, Rosato R, Gallamini A, Marinone C, Bergui L, Boccadoro M, Tarella C, Ladetto M. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia 2007 Febr; 1-9 (IF 8.296)

 Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster J, Murty VV, Shipp M, and Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 2006 Feb; 203: 311 – 317 (IF 14.51)

Ricca I, Compagno M, Ladetto M, Rocci A, Dell’Aquila M, Omede P, De Marco F, D’Antico S,, Caracciolo D, Ferrero D, Carlo-Stella C, Tarella C. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF. Leukemia 2005 Apr;19(4):644-51 (IF 8.296)

Compagno M, Mantoan B, Astolfi M, Boccadoro M, Ladetto M. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.. Methods Mol Med. 2005; 113:145-63. 

Ladetto M, Vallet S, Trojan A, Dell’Aquila M, Monitillo L, Rosato R, Santo L, Drandi D, Bertola A, Falco P, Cavallo F, Ricca I, De Marco F, Mantoan B, Bode-Lesniewska B, Pagliano G, Francese R, Rocci A, Astolfi M, Compagno M, Mariani S, Godio L, Lydia Marino L, Ruggeri M, Omede` P, Palumbo A, and Mario Boccadoro.  Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005 Jun 15; 105(12): 4784-91 (IF 10.56)

Ladetto M, Compagno M,  Ricca I, Pagano M, Rocci A, Astolfi M, Drandi D, Francia di Celle P, Dell’Aquila M, Mantoan B, Vallet S, Pagliano G, De Marco F, Francese R, Santo L, Cuttica A, Marinone C, Boccadoro M, Tarella C. Telomere length correlates  with histopatogenesis according to the germinal center in in mature B-cell lympho-prolipherative disorders. Blood 2004 Jun 15; 103(12):4644-9 (IF 10.56)

Ladetto M, Drandi D, Compagno M, Astolfi M, Volpato F, Voena C, Novarino A, Pollio B, Addeo A, Ricca I, Falco P, Cavallo F, Vallet S, Corradini P, Pileri A, Tamponi G, Palumbo A, Bertetto O, Boccadoro M, Tarella C. PCR-detectable nonneoplastic Bcl-2/IgH rearrangement are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. J Clin Oncol 2003 April 1; 21 (7): 1398-403 (IF 17.79)

Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, Vallet S, Dell’Aquila M, Alfarano A, Rossatto P, Rocci A. Vitolo U, Corradini P, Boccadoro M, Tarella C. Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. Exp Hematol  2003 Sep;31(9):784-8 (IF 3.106)

19-22 October 2011, Torino: SIC (Societa' Italiana di Cancerologia)

BACK TO THE FUTURE, Translating cancer research from bedside to bench and back

7-10 July 2012, Barcellona: European Association for Cancer Research (EACR), 22th Biennal Congress

From Basic Research to Personalized Cancer Treatment

October 2013, DANA Farber Cancer Institute, Boston, Symphosium:

Chromatin and DNA Repair

Dr Daniel Bauer (10/9/13) Harvard Medical School

An enhancer of BCL11A determines fetal hemoglobin level: implications for common genetic variation and translational potential for beta-globin disorders

Dr Louis Staudt (11/09/13) Harvard Medical School

Self ligand oncogenic signaling in human lymphomas

Dr Ari M. Melnick (12/09/13) Harvard Medical School

Epigenetic Basis of Hematologic Malignancies

Dr Randall T. Peterson (19/09/13) Harvard Medical School

Zebrafish screens for novel modifiers of development and disease

Dr Reinhold Forster (25/09/13) Harvard Medical School

Lymph node homing of immune cells via afferent lymphatics

Dr Mark Krasnow (15/10/13 ) Harvard Medical School

Mapping lung development, stem cells, and cancer at single cell resolution

Dr Thirmula Kanneganti (16/10/13) Harvard Medical School

Regulators of Inflammatory Responses

Dr Bradley Bernstein (21/11/13) Harvard Medical School

Epigenetic regulation and heterogeneity in cancer

Dr Shaun Coughlin (26/09/13 Ramzi S.Cotran Lecture) Harvard Medical School

Sphingosine-1-phosphate signaling in cardiovascular biology

Dr. Suzanne Topalian (30/10/13 Benacerraf Lecture) Harvard Medical School

Immune checkpoint blockade: A new paradigm for cancer therapy

 01/02/2011-31/07/2011 Laboratory of Dr. Frederick Alt-Immune Disease Institute- Children's Hospital, Boston

01/01/2013-31/12/2013 Laboratory of Prof.Roberto Chiarle-Department of Pathology-Children's Hospital, Boston